Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors
NATIONAL CANCER INSTITUTE
· United States · $8.01M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.